BerGenBio ASA (FRA:7BG0) Institutional Ownership : 0.84% (As of Jul. 01, 2025)

View and export this data going back to 2019. Start your Free Trial

What is BerGenBio ASA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BerGenBio ASA's institutional ownership is 0.84%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BerGenBio ASA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BerGenBio ASA's Float Percentage Of Total Shares Outstanding is 0.00%.

BerGenBio ASA Institutional Ownership Historical Data

The historical data trend for BerGenBio ASA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Institutional Ownership Chart

BerGenBio ASA Historical Data

The historical data trend for BerGenBio ASA can be seen below:

	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31	2025-04-30	2025-05-31
Institutional Ownership	3.13	2.05	2.05	1.86	1.86	1.84	1.84	1.83	1.71	0.84

BerGenBio ASA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

BerGenBio ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (FRA:7BG0) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BGBIO:Norway 0RU5:UK

Address

Nygardsgaten 114, Bergen, NOR, 5008

Website

https://www.bergenbio.com

BerGenBio ASA is a clinical-stage biopharmaceutical company developing drugs for aggressive diseases, including drug resistant and metastatic cancers and respiratory disease. Its product, bemcentinib (BGB324), is a selective, potent, oral small molecule AXL inhibitor that has been tested in a various indications including NSCLC, AML and severe respiratory infections.

BerGenBio ASA Headlines

No Headlines